Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 7/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | PRKDC | P78527 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16295257 | 0.84 | MEN1 (0.50) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL16307654 | 0.83 | MAP4K4 (0.45) | — | |
| SCHEMBL16296345 | 0.82 | KDM4E (0.48) | PTPN1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL9997048 | 0.82 | PIK3CG (0.47) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL16296373 | 0.81 | GAA (0.50) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL16296349 | 0.80 | CHEK1 (0.44) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL16296317 | 0.78 | KMT2A (0.42) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL16295121 | 0.76 | ATR (0.45) | ATR | |
| SCHEMBL16295855 | 0.75 | KDM4E (0.48) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL12970648 | 0.74 | PIK3CG (0.54) | PIK3CDPIK3CAPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-3008061-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BUB1B, PLK1, BRCA1 | PTPN1 543/4885PTPN2 962/4885KDM4E 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.